Our Pricing

Mounjaro Discount Code: save £20 with WEIGHTLOSSNEW

Published on: June 03, 2026

Searching for a verified mounjaro discount code uk pharmacy can trust? Cured Pharmacy offers £20 off your first Mounjaro prescription with code WEIGHTLOSSNEW, bringing genuine UK-licensed tirzepatide pens from £124.99. Our transparent pricing includes a free clinical consultation with UK prescribers, discreet delivery, and the lowest prices guaranteed across the UK.

How to Use Your Mounjaro Discount Code UK

Applying your discount code at Cured Pharmacy takes under three minutes. After completing your free online consultation with a UK-registered prescriber, simply enter WEIGHTLOSSNEW at checkout to receive your discount. The code applies to your first Mounjaro prescription order and can be combined with our price-match guarantee, ensuring you always receive competitive UK pricing.

Unlike promotional codes that expire within days, WEIGHTLOSSNEW remains valid for new patients throughout 2025. Your final price depends on the prescribed dose—2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, or 15mg—which your prescriber determines based on your medical history, current weight, and treatment goals. All consultations are conducted by GMC-registered clinicians, and prescriptions are dispensed by our superintendent pharmacist Tarun Kumar (GPhC 2233073).

Every Mounjaro pen supplied through Cured Pharmacy is sourced directly from UK-licensed wholesalers and carries full MHRA approval. We never supply grey-market or imported formulations, ensuring you receive the same quality medication dispensed by high-street pharmacies, but with transparent upfront pricing and the convenience of home delivery.

Mounjaro Price Comparison: Why Cured Pharmacy Offers the Cheapest Mounjaro UK

Cured Pharmacy maintains the lowest Mounjaro prices in the UK through direct relationships with licensed wholesalers and a streamlined online model that eliminates physical premises costs. While typical market rates vary significantly across providers, our starting price remains consistently competitive, with no hidden consultation fees or delivery charges for orders dispatched within the UK.

Our pricing structure is transparent from the outset. Before you begin your consultation, you'll see exactly what each dose costs, allowing you to make an informed decision. Many providers advertise low entry prices but add consultation fees, membership subscriptions, or premium delivery charges that inflate the true cost. At Cured Pharmacy, the price you see includes your medication, clinical assessment, and standard UK delivery.

We also operate a price-match guarantee. If you find genuine UK-licensed Mounjaro at a lower price from another GPhC-registered pharmacy, we'll match it. This commitment ensures you're always receiving the best value without compromising on safety, regulatory compliance, or clinical oversight.

Understanding Mounjaro Pricing Across Doses

Mounjaro treatment follows a dose-escalation schedule, starting at 2.5mg weekly and increasing every four weeks until you reach your maintenance dose. Higher doses naturally cost more due to the increased quantity of active tirzepatide per pen. Your prescriber will determine the appropriate escalation schedule based on your tolerance and weight loss progress, ensuring you achieve optimal results while minimising side effects.

Most patients reach a maintenance dose of 10mg or 15mg, where clinical trials demonstrated the greatest average weight reduction. The SURPASS-3 trial showed participants on 15mg tirzepatide achieved an average 22.5% body weight reduction over 72 weeks, compared to 9.5% with placebo [1]. Your UK prescriber will review your progress at regular intervals and adjust your dose accordingly, always prescribing the clinically appropriate strength rather than the highest available.

How Mounjaro Works: The Science Behind Tirzepatide

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. Unlike single-pathway treatments such as semaglutide, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors. This dual action enhances insulin secretion, reduces glucagon release, slows gastric emptying, and significantly reduces appetite through central nervous system pathways [2].

The dual mechanism produces superior weight loss outcomes compared to GLP-1-only treatments. In head-to-head trials, tirzepatide demonstrated greater average body weight reduction and a higher proportion of patients achieving clinically significant weight loss thresholds of 15% and 20% [1][3]. The medication also improves cardiovascular risk markers, including blood pressure, lipid profiles, and inflammatory markers, though it is not licensed specifically for cardiovascular prevention in the UK.

Tirzepatide's once-weekly subcutaneous injection offers convenience and consistent therapeutic levels throughout the week. The medication has a half-life of approximately five days, allowing steady-state concentrations to be reached after four weeks of treatment. This pharmacokinetic profile supports the four-week dose escalation schedule, giving your body time to adjust before increasing to the next strength.

Clinical Trial Evidence for Mounjaro

The SURMOUNT-1 trial, published in the New England Journal of Medicine, enrolled 2,539 adults with obesity or overweight plus weight-related comorbidities [1]. Participants receiving 15mg tirzepatide weekly lost an average of 20.9% of their body weight over 72 weeks, compared to 3.1% in the placebo group. More than half of participants on the highest dose achieved at least 20% weight reduction, a threshold rarely seen with lifestyle interventions alone.

Safety data from the SURPASS trial programme, which included over 8,000 participants, showed tirzepatide was generally well tolerated [3]. The most common side effects were gastrointestinal—nausea, diarrhoea, constipation, and vomiting—which typically occurred during dose escalation and diminished over time. Serious adverse events were rare and comparable to other GLP-1 receptor agonists. Your UK prescriber will review your medical history to ensure Mounjaro is appropriate for you, considering contraindications such as personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Mounjaro vs Wegovy: Comparing the Two Leading Weight Loss Injections

Both Mounjaro and Wegovy are injectable medications licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity. While Wegovy contains semaglutide—a GLP-1 receptor agonist—Mounjaro's tirzepatide offers dual GIP/GLP-1 activity, which clinical trials suggest may produce greater average weight loss [1][2].

The STEP trials demonstrated that semaglutide 2.4mg weekly resulted in an average 14.9% body weight reduction over 68 weeks, a clinically meaningful outcome [2]. However, direct and indirect comparisons suggest tirzepatide's dual mechanism produces superior results, with the highest doses achieving average reductions exceeding 20% [1]. Individual responses vary considerably, and some patients may achieve excellent results with semaglutide while experiencing intolerable side effects with tirzepatide, or vice versa.

Cost is another consideration. Wegovy is generally priced lower than Mounjaro across UK pharmacies, starting from a more accessible entry point. For patients seeking the most potent weight loss medication currently available, Mounjaro may justify the higher investment. For those prioritising affordability while still accessing a highly effective GLP-1 treatment, Wegovy represents excellent value. Your prescriber will discuss both options during your consultation, considering your budget, weight loss goals, medical history, and personal preferences.

Who Can Use Mounjaro? Eligibility and Prescriber Assessment

Mounjaro is licensed in the UK for adults with a body mass index of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea. It is not licensed for cosmetic weight loss in individuals with a healthy BMI, and prescribers must assess clinical need before issuing a prescription.

During your free online consultation at Cured Pharmacy, a UK-registered prescriber will review your medical history, current medications, and weight loss goals. They'll assess contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or diabetic retinopathy. Pregnant or breastfeeding women cannot use Mounjaro, and women of childbearing potential should use effective contraception during treatment.

Your prescriber will also evaluate whether you've attempted lifestyle modifications—dietary changes and increased physical activity—before starting pharmacotherapy. NICE guidance emphasises that weight loss medications should complement, not replace, behaviour change programmes. If your prescriber determines Mounjaro is appropriate, they'll issue a prescription starting at the 2.5mg dose, with instructions for dose escalation every four weeks based on your tolerance and progress.

What to Expect During Your Consultation

Cured Pharmacy's online consultation takes under three minutes to complete and covers your medical history, current medications, allergies, previous weight loss attempts, and treatment goals. You'll provide your height, weight, and details of any weight-related health conditions. The questionnaire is designed to give your prescriber all the information they need to make a safe, informed prescribing decision.

If approved, your prescription is sent electronically to our dispensary, where superintendent pharmacist Tarun Kumar and his team prepare your medication for dispatch. Most orders are dispatched within 24 hours on weekdays, arriving via discreet, unbranded packaging. If your prescriber determines Mounjaro is not suitable—perhaps due to a contraindication or insufficient clinical need—they'll explain why and may suggest alternative treatments such as Wegovy, Saxenda, or Orlistat.

How to Order Mounjaro Online from Cured Pharmacy

Ordering Mounjaro from Cured Pharmacy is straightforward and fully compliant with UK regulations. Start by clicking 'Start Assessment' on the Mounjaro product page, which takes you to the online consultation. Complete the questionnaire honestly and thoroughly—accurate information ensures your prescriber can make the safest decision. Once submitted, a UK-registered clinician reviews your consultation, usually within a few hours during working days.

If your prescription is approved, you'll receive an email confirmation with tracking details. Apply your discount code WEIGHTLOSSNEW at checkout to receive your discount on your first order. Payment is processed securely, and your medication is dispensed by our GPhC-registered pharmacy team. All Mounjaro pens are supplied in their original manufacturer packaging with patient information leaflets, ensuring you have all the guidance you need for safe administration.

Your first prescription will be for the 2.5mg starting dose, which you'll use for four weeks. After this initial period, you'll need a follow-up consultation to escalate to 5mg, then 7.5mg, and so on until you reach your maintenance dose. Cured Pharmacy will send reminders when it's time to reorder and escalate, ensuring continuity of treatment. Our clinical team is available by phone on (+44) 116 4646009 if you have questions or experience side effects that concern you.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143–155. https://doi.org/10.1016/S0140-6736(21)01324-6 [accessed 13 August 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals, and outcomes cannot be guaranteed.